Revlimid (lenalidomide) is a brand-name drug that doctors may prescribe to treat certain cancers of the blood. If a person has a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) ...
Doctors prescribe Revlimid (lenalidomide) to treat certain blood cancers, including multiple myeloma, mantle cell lymphoma, and others. The drug is not safe to take while pregnant, and doctors avoid ...
Summit, N.J., June 29 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...
The prescribed dosage for Revlimid (lenalidomide) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis and medical history, may affect your ...
Revlimid (lenalidomide) can cause side effects that range from mild to serious. More common side effects include nausea, fatigue, and anemia. Most mild side effects of Revlimid are temporary and go ...
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...
Darzalex and Revlimid combination therapy post-transplant improved MRD negativity and progression-free survival in multiple myeloma patients compared to Revlimid alone. The combination therapy showed ...
U.S. Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma "There remains a tremendous unmet need for patients ...
A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL). The trial, ...
Revlimid (lenalidomide) may interact with drugs like estrogens, erythropoietin-stimulating agents, denosumab, digoxin, and warfarin, which might increase the risk of blood clots or side effects.
Low-dose Revlimid delayed transfusion dependency and improved treatment response rates in non-transfusion dependent MDS patients. Revlimid reduced the risk of transfusion dependency by 69.8% compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results